Related Experiment Video

Updated: Dec 29, 2025

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.2K

Neuropathological Findings in Parkinson's Disease With Mild Cognitive Impairment

Molly G Knox1, Charles H Adler1, Holly A Shill2

  • 1Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA.

Movement Disorders : Official Journal of the Movement Disorder Society
|February 9, 2020
PubMed
Abstract

Insights

Parkinson's disease with mild cognitive impairment (PD-MCI) shows varied brain pathologies. Nonamnestic PD-MCI had more severe Lewy body pathology than amnestic PD-MCI.

Area of Science:

  • Neuroscience
  • Neuropathology
  • Gerontology

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder.
  • Mild cognitive impairment (MCI) is common in PD.
  • Neuropathological studies on PD with MCI (PD-MCI) are limited, often showing mixed Lewy body and Alzheimer's disease pathologies.

Purpose of the Study:

  • To investigate the specific neuropathological underpinnings of PD-MCI.
  • To compare pathologies in amnestic MCI (A-MCI) versus nonamnestic MCI (NA-MCI) within PD.

Main Methods:

  • Utilized data from the Arizona Study of Aging and Neurodegenerative Disorders.
  • Analyzed neuropathological findings from 25 autopsied subjects with PD-MCI.
  • Compared Lewy body and Alzheimer's disease pathologies in A-MCI and NA-MCI subtypes.

Main Results:

  • Identified significant pathological heterogeneity in PD-MCI.
  • Observed varying stages of Lewy body pathology, Alzheimer's disease pathology, and cerebral amyloid angiopathy.
  • Found a significant increase in severe Lewy body pathology (neocortical stage) in NA-MCI (63%) compared to A-MCI (21%, P=0.032).

Conclusions:

  • Distinct neuropathological changes contribute to different PD-MCI phenotypes.
  • Nonamnestic PD-MCI is associated with more advanced Lewy body pathology.
  • Further research is needed to understand the full spectrum of PD-MCI pathology.
Keywords:
Parkinson's diseasemild cognitive impairmentneurodegenerative disordersneuropathology

More Related Videos

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.0K
Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

14.5K

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.0K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
876
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
458
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
699